Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas.

Seventy-two small-sized (<or=2 cm in diameter) lung adenocarcinomas consisting of 15 noninvasive and 57 invasive tumors were subjected to whole genome allelic imbalance (AI) scanning and mutational analysis of the EGFR, KRAS, and TP53 genes to elucidate genetic pathways of early-stage lung adenocarcinomas. The chromosome 13q13 region showed the most frequent AI (58%) and was affected at similar frequencies between noninvasive and invasive tumors (53% and 60%, respectively), as EGFR and KRAS mutations were. The number of AI regions as well as the frequency of TP53 mutations in invasive tumors was significantly higher than those in noninvasive ones [9.8 +/- 5.6 versus 4.8 +/- 2.8 (P = 0.00002) and 61% versus 13% (P = 0.001), respectively]. In particular, AIs at the chromosome 11p11-p12, 17p12-p13, and 18p11 regions in invasive tumors were significantly more frequent than those in noninvasive ones (P < 0.01). The results indicated that noninvasive tumors were developed by EGFR, KRAS, and 13q alterations and progressed to invasive ones by subsequent alterations of several tumor suppressor genes, including those on 11p11-p12, 17p12-p13, and 18p11 and TP53. AI at 8p21 was significantly more frequent in advanced stages (>IA) and associated with worse prognoses (P = 0.04) and, thus, would be involved in invasion and/or metastasis of adenocarcinoma cells and useful for the prediction of prognosis of patients with small-sized lung adenocarcinoma.

[1]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  S. Hirohashi,et al.  Deletion of three distinct regions on chromosome 13q in human non‐small‐cell lung cancer , 1997, International journal of cancer.

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  J. Yokota,et al.  Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer , 2008, Oncogene.

[5]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[6]  J. Minna,et al.  Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. , 2002, Clinical Cancer Research.

[7]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[8]  Luc Girard,et al.  An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. , 2004, Cancer research.

[9]  J. Minna,et al.  Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. , 1999, Cancer research.

[10]  A. Nicholson,et al.  Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  M. Amin,et al.  Surgical margin and gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance , 2004, The Prostate.

[12]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Yokota,et al.  Clonal and Parallel Evolution of Primary Lung Cancers and Their Metastases Revealed by Molecular Dissection of Cancer Cells , 2007, Clinical Cancer Research.

[14]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[15]  S. Hirohashi,et al.  Comparative allelotype of early and advanced stage non‐small cell lung carcinomas , 1996, Genes, chromosomes & cancer.

[16]  B. Agnarsson,et al.  Chromosome 8p alterations in sporadic andBRCA2 999del5 linked breast cancer , 2000, Journal of medical genetics.

[17]  O. Miettinen,et al.  Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .

[18]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[19]  J. Yokota,et al.  Molecular footprints of human lung cancer progression , 2004, Cancer science.

[20]  Y. Yatabe,et al.  Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas , 2007, The Journal of pathology.

[21]  J. Minna,et al.  Prevalence and specificity of LKB1 genetic alterations in lung cancers , 2007, Oncogene.

[22]  L. Mariani,et al.  Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. , 2005, Cancer research.

[23]  Y. Nakamura,et al.  Allelotype of non-small cell lung carcinoma--comparison between loss of heterozygosity in squamous cell carcinoma and adenocarcinoma. , 1992, Cancer research.

[24]  E. Bergstralh,et al.  Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer , 1998, Genes, chromosomes & cancer.

[25]  Kenji Suzuki,et al.  Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[26]  S. Toyooka,et al.  Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. , 2006, Cancer research.

[27]  H. S. Kim,et al.  Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. , 1999, Cancer research.

[28]  J. Minna,et al.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. , 2000, Cancer research.

[29]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[30]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[31]  T. Oda,et al.  Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. , 2001, Cancer research.

[32]  Setsuo Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .

[33]  Y. Nakamura,et al.  Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. , 1992, Cancer research.

[34]  J. Minna,et al.  Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types , 1998, Genes, chromosomes & cancer.

[35]  Kenji Suzuki,et al.  Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma , 2006, International journal of cancer.

[36]  志関 雅幸.  Frequent allelic losses on chromosomes 2q,18q,and 22q in advanced non-small cell lung carcinoma , 1999 .

[37]  Y. Nakamura,et al.  Allelic loss at chromosome band 8p21.3‐p22 is associated with progression of hepatocellular carcinoma , 1993, Genes, chromosomes & cancer.

[38]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.